Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.99
+9.9%
$2.49
$1.61
$4.94
$155.86M3.34916,578 shs1.66 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$305.71
+3.0%
$263.06
$122.80
$306.10
$8.75B0.5287,707 shs470,347 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$56.85
-2.9%
$51.06
$23.30
$66.06
$3.65B2.221.53 million shs1.09 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
0.00%+2.64%+8.80%+20.35%+75.48%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+13.13%+12.29%+8.78%+116.89%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+0.15%+14.40%+18.91%+78.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.99
+9.9%
$2.49
$1.61
$4.94
$155.86M3.34916,578 shs1.66 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$305.71
+3.0%
$263.06
$122.80
$306.10
$8.75B0.5287,707 shs470,347 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$56.85
-2.9%
$51.06
$23.30
$66.06
$3.65B2.221.53 million shs1.09 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
0.00%+2.64%+8.80%+20.35%+75.48%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
0.00%+13.13%+12.29%+8.78%+116.89%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+0.15%+14.40%+18.91%+78.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.70
Moderate Buy$10.00234.45% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.83
Moderate Buy$324.116.02% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.57-0.49% Downside

Current Analyst Ratings Breakdown

Latest TWST, BDTX, and KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Reiterated RatingOutperform$300.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Boost Price TargetBuy$371.00 ➝ $378.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
5/4/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Reiterated RatingBuy$310.00
4/29/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Reiterated RatingBuy
4/29/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Boost Price TargetBuy$10.00 ➝ $11.00
4/23/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
UpgradeStrong-Buy
4/21/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
UpgradeSell (D)Sell (D+)
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$70M2.45$0.58 per share5.16$1.97 per share1.52
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M23.16$7.51 per share40.70$43.31 per share7.06
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M9.40N/AN/A$7.31 per share7.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.77N/AN/AN/AN/A-29.00%-23.03%5/11/2026 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.4840.8729.06N/A53.92%19.25%17.62%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A

Latest TWST, BDTX, and KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A
5/4/2026Q1 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.45$1.83+$0.38$1.83$112.11 million$116.36 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
3/16/2026Q4 2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A
2/17/2026Q4 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.62$1.70+$0.08$1.70$105.30 million$107.11 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
8.42
8.42
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.46
9.56
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
3.37

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
5.97%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9057.30 million53.88 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21029.48 million25.62 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Gets a Buy from Guggenheim
Twist Bioscience Charts Profitable Path Amid Strong Growth
Twist Bioscience Corp (TWST) Climbed on Earnings Beat
Twist Bioscience Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$2.99 +0.27 (+9.93%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$3.03 +0.04 (+1.44%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$305.71 +9.01 (+3.04%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$311.14 +5.43 (+1.78%)
As of 05/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$56.85 -1.69 (-2.89%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$56.76 -0.09 (-0.16%)
As of 05/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.